文献速递艾滋病与性传播感染

CAP256V2LS固定剂量与按体重给药在女性HIV预防中的群体药代动力学比较

Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究基于CAPRISA 012B试验,在年轻HIV阴性女性中评估广谱中和抗体CAP256V2LS皮下给药的群体药代动力学。模型模拟显示,1200 mg固定剂量与20 mg/kg按体重给药暴露量相当,固定剂量可减少血药浓度变异和产品浪费。

要点

  • 1200 mg固定剂量与20 mg/kg按体重给药暴露量相当。
  • 固定剂量减少血药浓度变异和产品浪费。
  • 体重60-93 kg女性中固定剂量安全性与药代动力学特征相似。

核心结论

  • 对于体重60-93 kg的女性,CAP256V2LS 1200 mg固定剂量与按体重给药产生相似的不良事件和药代动力学特征。
  • 固定剂量相比按体重给药降低了血浆浓度变异和产品浪费。

研究设计与样本

  • CAPRISA 012B是一项首次人体、1期剂量递增试验,在南非年轻HIV阴性女性中开展。
  • 评估CAP256V2LS单用或与VRC07-523LS联用的皮下给药,按体重5-20 mg/kg或固定1200 mg给药。
  • 建立群体药代动力学模型,并模拟扩展至34.2-119 kg的假设体重范围。

主要发现

  • 模型模拟显示1200 mg固定剂量与20 mg/kg按体重给药暴露量相当。
  • 生物利用度和清除率的个体间变异分别为0.212和0.019,在固定剂量和按体重给药间一致。
  • 按体重给药5 mg/kg、10 mg/kg和20 mg/kg的平均浪费量分别为265.8 mg、433.4 mg和324.2 mg。

临床怎么用

  • 在体重60-93 kg的女性中,可考虑采用1200 mg固定剂量替代按体重给药以简化HIV预防方案。

局限性

  • 研究对象为年轻HIV阴性女性,结果外推至其他人群需谨慎。
  • 模拟扩展至34.2-119 kg体重范围为假设性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the development of broadly neutralizing monoclonal antibodies (bNAb) for HIV prevention, there is a need for simpler dosing strategies. This study assessed whether fixed dosing achieves comparable systemic bNAb concentrations to weight-based dosing across a range of weights. METHODS: The CAPRISA 012B trial was a first-in-human, Phase 1 dose-escalation study conducted in young, HIV-negative women (median age 25 years; IQR: 22-29) in South Africa, evaluating the subcutaneous administration of CAP256V2LS alone and in combination with VRC07-523LS. Weight-based dosing between 5 and 20 mg/kg was assessed. A fixed 1200 mg dose of CAP256V2LS and VRC07-523LS, administered alone or in combination, was evaluated in women weighing from 59.5 kg to 93.2 kg, with a median weight of 78.3 kg (IQR: 67.2-81.5). A population pharmacokinetic model was developed to describe and predict the concentration-time profiles of CAP256V2LS in participants. Model-based simulations then extended this analysis across a broader hypothetical weight range (34.2-119 kg). RESULTS: Model-based simulations revealed comparable exposure between the 1200 mg fixed-dose and the 20 mg/kg weight-based dosing regimens. Inter-individual variability in bioavailability and clearance was 0.212 and 0.019, respectively, and was consistent across both fixed-dose and weight-based dosing, regardless of the route of administration. Weight-based dosing of CAP256V2LS led to a mean wastage of 265.8 mg for the 5 mg/kg dose, 433.4 mg for the 10 mg/kg dose, and 324.2 mg for the 20 mg/kg dose. CONCLUSIONS: For women weighing 60-93 kg, a fixed-dose of 1200 mg of CAP256V2LS produced similar adverse events and pharmacokinetic profiles as weight-based dosing. The fixed dose reduced variability in the plasma concentrations and product wastage compared with weight-based dosing.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mahomed S, Beliveau M, Heredia-Ortiz R, et al. Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women. J Antimicrob Chemother. 2025. PMID: 40458046. doi:10.1093/jac/dkaf181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。